Skip to main content

Nippon Shokubai in HDO licence

Nippon Shokubai has concluded a licence agreement with its Japanese compatriot and affiliate company, Rena Therapeutics, to make and sell heteroduplex oligonucleotide (HDO) as a research reagent to industry and academia in all countries where it is covered by patents. Rena has existing licences with Ionis Pharmaceuticals and Takeda Pharmaceutical.

Subscribe to Rena Therapeutics